Skip to main
SPTX

SPTX Stock Forecast & Price Target

SPTX Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Seaport Therapeutics is a strong potential investment due to its innovative and promising products in the neuropsychiatric disorder market, including GlyphAllo, Glyph2BLSD, and GlyphAgo. The company's focus on bypassing first-pass metabolism and reducing side effects makes their drugs stand out in the crowded prescription market. With a successful Phase 1 trial and a favorable outlook, Seaport has potential for growth and acquisition, solidifying its position as a leader in the treatment of depression, anxiety, and other neuropsychiatric disorders.

Bears say

Seaport Therapeutics is facing potential challenges in the rapidly advancing clinical programs for its two most mature clinical-stage assets, which may lead to delayed key catalysts expected in the next several quarters. Additionally, the company's planned Phase 2b trials for its pipeline products are not expected to yield results until 2028, causing potential concerns for investors. The company also faces competition from other companies developing innovative treatments in the neuropsychiatry space.

SPTX has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Seaport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Seaport Therapeutics Inc (SPTX) Forecast

Analysts have given SPTX a Strong Buy based on their latest research and market trends.

According to 6 analysts, SPTX has a Strong Buy consensus rating as of Sep 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Seaport Therapeutics Inc (SPTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.